THE BODY MASS INDEX INFLUENCES THE ACHIEVEMENT RATIO OF TARGET BLOOD PRESSURE BY SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN JAPANESE TYPE 2 DIABETES PATIENTS WITH CKD

Introduction. Insulin resistance is a well-known leading factor in the development of metabolic syndrome. The aim of this study was to evaluate metabolic effects of metformin added to sulfonylurea in unsuccessfully treated type 2 diabetic patients with metabolic syndrome. Material and methods. A group of thirty subjects, with type 2 diabetes, secondary sulfonylurea failure and metabolic syndrome were administered the combined therapy of sulfonylurea plus metformin for six months. Metformin 2000 mg/d was added to previously used sulfonylurea agent in maximum daily dose. Antihypertensive and hypolipemic therapy was not changed. The following parameters were assessed at the beginning and after six months of therapy: glycemic control, body mass index, waist circumference, blood pressure, triglycerides, total cholesterol and its fractions, homeostatic models for evaluation of insulin resistance and secretion (HOMA R, HOMA B) and C- peptide. Results. Glycemic control was significantly improved after six months of the combined therapy: (fasting 7.89 vs. 10.61 mmol/l. p<0.01; postprandial 11.12 vs. 12.61 mmol/l. p<0.01, p<0.01; glycosylated hemoglobin 6.81 vs. 8.83%. p<0.01). the body mass index and waist circumference were significantly lower (26.7 vs. 27.8 kg/m2, p<0.01 and 99.7 vs. 101.4 cm for men, p<0.01; 87.2 vs. 88.5 for women, p<0.01). Fasting plasma triglycerides decreased from 3.37 to 2.45 mmol/l (p<0.001) and HOMA R from 7.04 to 5.23 (p<0.001). No treatment effects were observed on blood pressure, cholesterol, and residual insulin secretion. Conclusion. Administration of metformin in type 2 diabetes with metabolic syndrome decreased cardiovascular risk factors by reducing glycemia, triglycerides, BMI, central obesity and insulin resistance.

Download Full-text

Frequency of Genital Infections According to Body Mass Index in Dapagliflozin-treated Patients with Type 2 Diabetes Mellitus

Experimental and Clinical Endocrinology & Diabetes Reports ◽

10.1055/s-0043-101823 ◽

2017 ◽

Vol 04 (01) ◽

pp. e1-e4

Author(s):

Gottfried Rudofsky ◽

Tanja Haenni ◽

John Xu ◽

Eva Johnsson

Keyword(s):

Type 2 Diabetes ◽

Body Mass Index ◽

Body Mass ◽

The Body ◽

Baseline Body Mass Index ◽

Obese Patients ◽

Genital Infections ◽

Increased Risk ◽

Three Body

Abstract Genital infections are associated with sodium glucose co-transporter 2 inhibitors such as dapagliflozin. Since patients with Type 2 diabetes are at increased risk of genital infections, and obesity is a risk factor for infections, obese patients with Type 2 diabetes could be more susceptible to genital infections when treated with sodium glucose co-transporter 2 inhibitors. This pooled dataset assessed the frequency of genital infections according to baseline body mass index in patients treated with dapagliflozin 10 mg. Data were pooled from 13 studies of up to 24 weeks’ duration (dapagliflozin N=2 360; placebo N=2 295). Frequency of genital infections was compared between three body mass index subgroups (<30, ≥30−< 35 and ≥35 kg/m2). Genital infections were reported in 130 (5.5%) patients receiving dapagliflozin and 14 (0.6%) patients receiving placebo; none of which were serious. Genital infections were more common in women (84/130 [64.6%]) than in men (46/130 [35.4%]) treated with dapagliflozin. In the body mass index < 30, ≥ 30−< 35 and ≥ 35 kg/m2 dapagliflozin-treated subgroups, 38/882 (4.3%), 47/796 (5.9%) and 45/682 (6.6%) patients presented with genital infections, respectively. Although the frequency was low overall and relatively similar between subgroups, there was a trend towards an increase in genital infections in patients with a higher body mass index. This trend is unlikely to be clinically relevant or to affect suitability of dapagliflozin as a treatment option for obese patients with Type 2 diabetes, but rather should influence advice and counselling of overweight patients on prevention and treatment of genital infections.

Download Full-text

Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/a-0636-3961 ◽

2018 ◽

Vol 128 (03) ◽

pp. 170-181 ◽

Cited By ~ 3

Author(s):

Rainer Lundershausen ◽

Sabrina Müller ◽

Mahmoud Hashim ◽

Joachim Kienhöfer ◽

Stefan Kipper ◽

...

Keyword(s):

Quality Of Life ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Body Mass Index ◽

Glycemic Control ◽

Body Mass ◽

Severe Hypoglycemia ◽

Insulin Initiation

Abstract Purpose To assess quality of life, glycemic control, and safety/tolerability associated with liraglutide versus insulin initiation in patients with type 2 diabetes in Germany. Methods Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician’s decision and followed for 52 weeks. The primary objective was to evaluate Audit of Diabetes-Dependent Quality of Life (ADDQoL) scores. Results At baseline, the liraglutide group was younger and had shorter type 2 diabetes duration, lower glycated hemoglobin (HbA1c), higher body mass index, and a lower prevalence of certain diabetes-related complications than the insulin group (all p<0.05). ADDQoL average weighted impact scores improved numerically in both groups from baseline to 52 weeks (mean difference [95% confidence interval], liraglutide vs. insulin: 0.159 [−0.023;0.340]; not significant). Changes in general wellbeing and five ADDQoL domains significantly favored liraglutide (remaining 14 domains, not significant). HbA1c reductions were greater with insulin than liraglutide (−2.0% vs. −1.2%; p<0.01); however, mean HbA1c after 52 weeks was 7.2% in both groups. Compared with insulin, liraglutide significantly decreased body mass index (−1.54 kg/m2 vs. +0.27 kg/m2; p<0.001), systolic blood pressure (−5.03 mmHg vs. −1.03 mmHg; p<0.01) and non-severe hypoglycemia (0.85% vs. 4.55% at 52 weeks; p<0.01). Adverse drug reactions were reported for<3% of patients in both groups. Conclusions Liraglutide improved certain ADDQoL components and reduced body mass index, systolic blood pressure, and non-severe hypoglycemia versus insulin. Both treatments improved glycemic control.

Download Full-text

Effectiveness of PRECEDE model for health education on changes and level of control of HbA1c, blood pressure, lipids, and body mass index in patients with type 2 diabetes mellitus

BMC Public Health ◽

10.1186/1471-2458-11-267 ◽

2011 ◽

Vol 11 (1) ◽

Cited By ~ 26

Author(s):

Miguel A Salinero-Fort ◽

Enrique Carrillo-de Santa Pau ◽

Francisco J Arrieta-Blanco ◽

Juan C Abanades-Herranz ◽

Carmen Martín-Madrazo ◽

...

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Body Mass Index ◽

Type 2 Diabetes Mellitus ◽

Health Education ◽

Body Mass

Download Full-text

Effects of adherence to the newly initiated dapagliflozin on body mass index and blood pressure in type 2 diabetes

10.26226/morressier.59d5184bd462b80296ca330c ◽

2017 ◽

Author(s):

Negalur Benny

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Body Mass Index ◽

Body Mass

Download Full-text

CHARACTERISTICS OF BLOOD PARAMETERS OF YAKUT MEN WITH TYPE 2 DIABETES DEPENDING ON THE SOMATOTYPE

“Educational bulletin “Consciousness” ◽

10.26787/nydha-2686-6846-2020-22-11-45-49 ◽

2020 ◽

Vol 22 (11) ◽

pp. 45-49

Author(s):

Alekseeva V.A. ◽

Zolotaryov N.A.

Keyword(s):

Type 2 Diabetes ◽

Body Mass Index ◽

Body Mass ◽

Statistical Processing ◽

Blood Parameters ◽

The Body ◽

Transverse Diameter ◽

Diagnostic Laboratory ◽

Anthropometric Study

The aim of the work was to identify the features of biochemical blood parameters of Yakut men with type 2 diabetes depending on the Rees-Eizenk somatotype. We examined 40 men of yakut nationality with an established diagnosis of "type 2 diabetes", aged 38 to 69 years (average age 57,4 years). The anthropometric study included measurements of body length, body weight, body circumference (chest circumference, waist and buttock circumference), and body diameters (transverse diameter of the chest, anterior-posterior diameter of the chest). The body mass index (BMI) was calculated. Somatotyping was performed using the Rees-Eizenk index. The index value of the examined men was divided into pyknic, normosthenic and asthenic somatotype. Data from the biochemical blood test were copied from the patients ' medical history. All laboratory tests were conducted in the clinical and diagnostic laboratory of the Yakut city clinical hospital. Statistical processing of the obtained scientific material was carried out by the method of variation statistics using the SPSS application software package for Windows (version 17,0). The analysis was performed using parametric and nonparametric statistics. An anthropometric study of men with type 2 diabetes found that half of the subjects were obese according to their body mass index. A somatotypological study on the Rees-Eizenk index found a predominance of individuals with a pyknical somatotype. Asthenic somatotype was not detected in the examined group. More pronounced deviations of biochemical parameters of the pyknic men's blood from the standard parameters were found. The data obtained indicate a greater susceptibility to the development of type 2 diabetes in men with a pyknical somatotype.

Download Full-text